scholarly journals Predicting Wearing-Off of Parkinson’s Disease Patients Using a Wrist-Worn Fitness Tracker and a Smartphone: A Case Study

2021 ◽  
Vol 11 (16) ◽  
pp. 7354
Author(s):  
John Noel Victorino ◽  
Yuko Shibata ◽  
Sozo Inoue ◽  
Tomohiro Shibata
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prediction Models ◽  
Smartphone Application ◽  
Wearing Off ◽  
Fitness Tracker ◽  
Patients Experience ◽  
World Environment

Parkinson’s disease (PD) patients experience varying symptoms related to their illness. Therefore, each patient needs a tailored treatment program from their doctors. One approach is the use of anti-PD medicines. However, a “wearing-off” phenomenon occurs when these medicines lose their effect. As a result, patients start to experience the symptoms again until their next medicine intake. In the long term, the duration of “wearing-off” begins to shorten. Thus, patients and doctors have to work together to manage PD symptoms effectively. This study aims to develop a prediction model that can determine the “wearing-off” of anti-PD medicine. We used fitness tracker data and self-reported symptoms from a smartphone application in a real-world environment. Two participants wore the fitness tracker for a month while reporting any symptoms using the Wearing-Off Questionnaire (WoQ-9) on a smartphone application. Then, we processed and combined the datasets for each participant’s models. Our analysis produced prediction models for each participant. The average balanced accuracy with the best hyperparameters was at 70.0–71.7% for participant 1 and 76.1–76.9% for participant 2, suggesting that our approach would be helpful to manage the “wearing-off” of anti-PD medicine, motor fluctuations of PD patients, and customized treatment for PD patients.

scholarly journals Longitudinal prediction of falls and near falls frequencies in Parkinson’s disease: a prospective cohort study

2020 ◽  
Author(s):  
Beata Lindholm ◽  
Christina Brogårdh ◽  
Per Odin ◽  
Peter Hagell
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prospective Cohort ◽  
Prediction Models ◽  
Evidence Base ◽  
History Of ◽  
Short And Long Term ◽  
Near Falls ◽  
Short Time

Abstract Introduction and objective Several prediction models for falls/near falls in Parkinson’s disease (PD) have been proposed. However, longitudinal predictors of frequency of falls/near falls are poorly investigated. Therefore, we aimed to identify short- and long-term predictors of the number of falls/near falls in PD. Methods A prospective cohort of 58 persons with PD was assessed at baseline (mean age and PD duration, 65 and 3.2 years, respectively) and 3.5 years later. Potential predictors were history of falls and near falls, comfortable gait speed, freezing of gate, dyskinesia, retropulsion, tandem gait (TG), pain, and cognition (Mini-Mental State Exam, MMSE). After each assessment, the participants registered a number of falls/near falls during the following 6 months. Multivariate Poisson regression was used to identify short- and long-term predictors of a number of falls/near falls. Results Baseline median (q1–q3) motor (UPDRS) and MMSE scores were 10 (6.75–14) and 28.5 (27–29), respectively. History of falls was the only significant short-time predictor [incidence rate ratio (IRR), 15.17] for the number of falls/near falls during 6 months following baseline. Abnormal TG (IRR, 3.77) and lower MMSE scores (IRR, 1.17) were short-term predictors 3.5 years later. Abnormal TG (IRR, 7.79) and lower MMSE scores (IRR, 1.49) at baseline were long-term predictors of the number of falls/near falls 3.5 years later. Conclusion Abnormal TG and MMSE scores predict the number of falls/near falls in short and long term, and may be indicative of disease progression. Our observations provide important additions to the evidence base for clinical fall prediction in PD.

scholarly journals Long-Term Home-Monitoring Sensor Technology in Patients with Parkinson’s Disease—Acceptance and Adherence

Sensors ◽  
2019 ◽  
Vol 19 (23) ◽  
pp. 5169 ◽  
Author(s):  
Angela Botros ◽  
Narayan Schütz ◽  
Martin Camenzind ◽  
Prabitha Urwyler ◽  
Daniel Bolliger ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Home Monitoring ◽  
The Body ◽  
Sensor Technology ◽  
Patient Acceptance ◽  
System Usability Scale ◽  
Technical Advances ◽  
World Environment

Parkinson’s disease (PD) is characterized by a highly individual disease-profile as well as fluctuating symptoms. Consequently, 24-h home monitoring in a real-world environment would be an ideal solution for precise symptom diagnostics. In recent years, small lightweight sensors which have assisted in objective, reliable analysis of motor symptoms have attracted a lot of attention. While technical advances are important, patient acceptance of such new systems is just as crucial to increase long-term adherence. So far, there has been a lack of long-term evaluations of PD-patient sensor adherence and acceptance. In a pilot study of PD patients (N = 4), adherence (wearing time) and acceptance (questionnaires) of a multi-part sensor set was evaluated over a 4-week timespan. The evaluated sensor set consisted of 3 body-worn sensors and 7 at-home installed ambient sensors. After one month of continuous monitoring, the overall system usability scale (SUS)-questionnaire score was 71.5%, with an average acceptance score of 87% for the body-worn sensors and 100% for the ambient sensors. On average, sensors were worn 15 h and 4 min per day. All patients reported strong preferences of the sensor set over manual self-reporting methods. Our results coincide with measured high adherence and acceptance rate of similar short-term studies and extend them to long-term monitoring.

scholarly journals Donepezil and α-synuclein Constipation: A 48 Month Follow-Up

2021 ◽  
pp. 1-7
Author(s):  
Charles M. Lepkowsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Lewy Bodies ◽  
Symptom Improvement ◽  
Neurocognitive Disorder ◽  
Apparent Reduction

In a case study, four patients diagnosed at different stages of disease progression with the α‐synuclein or Lewy body disorders Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) were treated with the acetylcholinesterase inhibitor (AChEI) Donepezil to address the symptoms of constipation, obstipation and impaction. The use of Donepezil was associated with significant symptom reduction for each of the four patients. In follow-up studies conducted at intervals of six, twelve, eighteen, thirty-six and forty-eight months, symptom improvement was maintained with no apparent reduction in bowel motility, nor the emergence of any new symptoms. The results suggest that the AChEI Donepezil can have long-term benefit in reducing the symptoms of constipation, obstipation and impaction in patients with α-synuclein disorders. Keywords: Neurocognitive Disorder with Lewy Bodies, Parkinson’s disease, constipation, Donepezil, acetylcholinesterase inhibitor

scholarly journals Understanding Wearing-Off Symptoms in Parkinson’s Disease Patients using Wrist-Worn Fitness Tracker and a Smartphone

2022 ◽  
Vol 196 ◽  
pp. 684-691
Author(s):  
John Noel Victorino ◽  
Yuko Shibata ◽  
Sozo Inoue ◽  
Tomohiro Shibata
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Wearing Off ◽  
Fitness Tracker

scholarly journals Donepezil and α-synuclein Constipation: A 36 Month Follow-Up

2019 ◽  
pp. 1-7
Author(s):  
Charles M. Lepkowsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Lewy Bodies ◽  
Neurocognitive Disorder ◽  
Apparent Reduction ◽  
Term Benefit

A case study is described in which four patients diagnosed at different stages of disease progression with the α‐synuclein or Lewy body disorders Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) were treated with the acetylcholinesterase inhibitor (AChEI) Donepezil to address the symptoms of constipation, obstipation and impaction. In all four patients, the use of Donepezil was associated with significant symptom reduction, which was maintained at intervals of six, twelve, eighteen and thirty-six months, with no apparent reduction in bowel motility, nor the emergence of any new symptoms. The results suggest that the AChEI Donepezil can have long-term benefit in reducing the symptoms of constipation, obstipation and impaction in patients with α‐synuclein disorders. Keywords: Neurocognitive Disorder with Lewy Bodies, Parkinson’s disease, constipation, Donepezil, acetylcholinesterase inhibitor

scholarly journals Parkinson's Disease - Levodopa Complications

1999 ◽  
Vol 26 (S2) ◽  
pp. S13-S20 ◽  
Author(s):  
David B. King
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Management Strategies ◽  
Clinical Syndrome ◽  
Motor Fluctuations ◽  
Current Management ◽  
Resting Tremor ◽  
Wearing Off ◽  
Psychiatric Complications

Parkinson's disease is a readily recognized clinical syndrome, characterized by resting tremor, rigidity, bradykinesia and loss of postural reflexes. The introduction of levodopa transformed our management of this disease. As our experience has increased the long term side effects of levodopa have become more apparent. Levodopa complications comprise: wearing off, motor fluctuations, and psychiatric complications. The complexity of these clinical phenomena has been worked out with time and is now well-recognized. A number of management strategies can ameliorate these long-term complications. This article reviews the current management of late-stage Parkinson's disease.

Sign in / Sign up

Export Citation Format

Share Document